Doxycycline Decreases Atherosclerotic Lesions in the Aorta of ApoE-/- and Ovariectomized Mice with Correlation to Reduced MMP-2 Activity.

Atherogenic events promote changes in vessel walls, with alteration of the redox state, and increased activity of matrix metalloproteinases (MMPs). Thus, this study aims to evaluate aortic remodeling, MMP activity, and reactive oxygen species (ROS) levels after treatment with doxycycline in ApoE-/- and ovariectomized mice (OVX). Female ApoE-/--knockout mice (5 weeks) were submitted to ovariectomy surgery to induce experimental menopause. They then received chow enriched with 1% cholesterol to induce hypercholesterolemia. The animals were divided into two experimental groups: ApoE-/-/OVX vehicle and ApoE-/-/OVX doxycycline (30 mg/kg) administered by gavage once a day for 28 days (15th to the 18th week of life). Blood samples were collected to measure total cholesterol and fractions. The aorta was used for morphometry and to measure the activity and expression of MMP-2 and ROS levels. The ApoE-/-/OVX doxycycline group showed no change in total and fraction cholesterol levels. However, there was a reduction in ROS levels, MMP-2 expression, and activity that correlated with a decrease in atherosclerotic lesions relative to the ApoE-/-/OVX vehicle (p > 0.05). Therefore, we conclude that doxycycline in ApoE-/-/OVX animals promotes a reduction in atherosclerotic lesions by reducing ROS and MMP-2 activity and expression.

Bond stability of conventional adhesive system with MMP inhibitors to superficial and deep dentin.

PURPOSE: To evaluate the microshear bond strength (µSBS) to deep (DD) or superficial (SD) dentin (µSBS) overtime, nanoleakage (AG%), degree of conversion (DC%), water sorption (WSp), and solubility (WSl) of an adhesive system [Adper Single Bond 2(ASB)] containing matrix metalloproteinases (MMP) inhibitors [GM1489 (ASB-GM), Batimastat (ASB-BAT), or Chlorhexidine diacetate (ASB-CHX)]. ASB without inhibitor was used as control (CONTROL). MATERIALS AND METHODS: WSp and WSL were calculated based on ISO4049. DC% was analyzed using FT-IR spectroscopy. Dentin discs were used for µSBS evaluation. For AG%, resin-dentin beams were analyzed under scanning electronic microscopy. Data were analyzed using three-way ANOVA (AG% and µSBS) or ANOVA (DC%, WSp, WSl) and Tukey's HSD test. RESULTS: ASB-CHX presented the lowest DC%, lowest WSp, and highest WSl. ASB-GM reached the highest immediate µSBS in SD, only different from ASB-CHX. In DD, ASB-BAT and ASB-GM had the highest µSBS, statistically different from ASB-CHX. After twelve months, ASB-GM and ASB-BAT presented higher µSBS in SD when compared to CONTROL and ASB-CHX. In DD, ASB-GM reached the highest value, which was statistically different from CONTROL and ASB-CHX. CONTROL at both dentin depths and ASB-CHX at DD did not maintain bond stability. In SD after 12 months, ASB-BAT and ASB-GM decreased AG%. In DD, only ASB-GM reduced AG%. CONCLUSION: The ASB containing Batimastat and GM1489 maintained resin-dentin bond stability after 12 months for both dentin depths, without jeopardizing WSp, WSl, or DC% of the adhesive system. The ASB-GM presented greater µSBS after 12 months when compared with ASB. CLINICAL SIGNIFICANCE: Batimastat and GM1489 could be suitable for inclusion as an MMP-inhibitor into Single Bond to improve the bond stability to superficial and deep dentin, without jeopardize the physic-mechanical proprieties.

Effectiveness of pre-treatment with chlorhexidine in restoration retention: A 36-month follow-up randomized clinical trial.

OBJECTIVES: This study evaluated the effect of the pre-treatment with 2% chlorhexidine digluconate (CHX) as coadjutant in restoration retention of noncarious cervical lesions (NCCL), after 36 months of follow-up. METHODS: A randomized controlled split-mouth and triple-blind (operators, patients and evaluator) trial was carried out. Patients (n=42) with at least two non-carious cervical lesions were included. The teeth with NCCL were randomly assigned to two treatment groups: application of 2% CHX (experimental group) or a placebo solution (control group) for 60s after acid etching and before the adhesive application. A trained and calibrated examiner evaluated the restorations at baseline (1 week) and at each recall (6, 12, 24 and 36 months) using the FDI criteria. A total of 225 restorations were evaluated after 36-month follow-up. Data were subjected to survival analysis using the Kaplan-Meier method, and the log-rank test was used to evaluate the existence of differences between the survival curves (α=0.05). RESULTS: The restorations survival rate after 36 months of follow-up was 76.1%. There was no difference in the retention and failure rates between the experimental and the control group (p=0.968). There was an increased failure trend when restorations were located subgingival compared to those at the gingival level or supragingival. CONCLUSION: The pre-treatment with 2% chlorhexidine digluconate did not promote further restoration retention of noncarious cervical lesions. CLINICAL SIGNIFICANCE: The cavity pre-treatment with chlorhexidine for inhibition of hybrid layer degradation does not add any beneficial effect to the clinical performance of restorations.

Effect of Pre-treatment with Chlorhexidine on the Retention of Restorations: A Randomized Controlled Trial

This study aimed to evaluate the effect of chlorhexidine (CHX) application on etched dentin on the 6-month retention of restorations placed on non-carious cervical lesions (NCCLs). A randomized controlled split-mouth and triple blind trial was carried out. Patients (n=42) with at least two non-carious cervical lesions were included. NCCLs were randomly assigned to two groups: control (placebo solution) or test group (2% CHX solution for 60 s after acid etching and before the adhesive application). Class V restorations (n=169) were performed with an etch-and-rinse adhesive system and composite resin by 10 trained operators. A calibrated examiner evaluated the restorations at 1 week (baseline) and at 6 months using the FDI criteria. The primary outcome was retention of the restorations. The analysis of factors associated to failure of restorations was carried out by Fisher's exact test (α=0.05). After 6 months of follow-up, 3.4% (CI 95% 1.3-7.3) of the restorations failed. There was no statistically significant difference between control and CHX (p=0.920). Regarding the cavity variables, deeper (p=0.04), wider (p=0.004) and wedge-shaped (p=0.033) cavities failed more. Both treatments provided acceptable clinical performance of the restorations. The use of CHX as a adjuvant in dentin adhesion did not influence the retention of Class V restorations after 6 months of follow-up.

O objetivo deste estudo foi avaliar o efeito da aplicação de clorexidina (CRX) em dentina condicionada na retenção de restaurações confeccionadas em lesões cervicais não-cariosas (LCNC) após 6 meses. Ensaio clínico randomizado triplo cego do tipo boca dividida foi conduzido. Pacientes (n=42) com no mínimo duas LCNC foram incluídos. LCNC foram randomizadas em dois grupos: controle (solução placebo) ou grupo teste (aplicação de CRX 2% por 60 s após o condicionamento e antes da aplicação do adesivo). Restaurações Classe V (n=169) foram realizadas com adesivo de condicionamento ácido total e resina composta, por 10 operadores treinados. Um examinador calibrado avaliou as restaurações após 1 semana (base) e 6 meses usando os critérios da FDI. O desfecho primário foi retenção das restaurações. A análise dos fatores associados à falha das restaurações foi conduzida com Teste Exato de Fisher (α=0,05). Após 6 meses de acompanhamento, 3,4% (IC 95% 1,3-7,3) das restaurações falharam. Não houve diferença estatística entre os grupos CRX e controle (p=0,920). Com relação às variáveis das cavidades, cavidades mais profundas (p=0,024), largas (p=0,004) e em formato de cunha (p=0,033) falharam mais. Ambos os tratamentos (CRX e controle) proporcionaram performance clínica aceitável das restaurações. O uso de CRX como coadjuvante na adesão à dentina não influenciou a retenção das restaurações Classe V após 6 meses de acompanhamento. .